Abstract Search

ea0081oc11.3 | Oral Communications 11: Thyroid 2 | ECE2022

PD-1/PD-L1 inhibitors and immune-related thyroid toxicity according to pre-existing thyroid dysfunction and TPO antibody levels: a single centre experience

Gruosso Giovanni , Nervo Alice Anna , Basile Sara , Migliore Enrica , D'Angelo Valentina , Ferrari Matteo , Roux Anna , Piovesan Alessandro , Arvat Emanuela

Background: Immune checkpoint inhibitors (ICIs) have modified the outcome of several advanced malignancies. Thyroid dysfunctions (DYSTHYR) are the most common endocrine immune-related adverse events (IRAEs) during treatment with the programmed cell death protein-1 (PD-1) and its ligand (PD-L1) inhibitors. Data regarding predictive biomarkers enabling stratification of DYSTHYR risk are still limited.Patients and methods: We retrospectively analyzed patien...

0 shares

ea0081rc3.7 | Rapid Communications 3: Thyroid 1 | ECE2022

Immune-related thyroid dysfunctions during PD-1/PD-L1 inhibitors and their association to the oncological outcome: new evidence

Ferrari Matteo , Anna Nervo Alice , Basile Sara , Migliore Enrica , D'Angelo Valentina , Gruosso Giovanni , Rosso Daniela , Retta Francesca , Piovesan Alessandro , Arvat Emanuela

Background: Immune checkpoint inhibitors (ICIs) showed impressive results in several malignancies; however, a large spectrum of immune-related adverse events (IRAEs) may occur, including thyroid dysfunction (DYSTHYR). IRAEs seem to be associated with better cancer outcome; limited data suggested that thyroid toxicity could be a predictor of response to ICIs.Patients and methods: We retrospectively evaluated all patients who started treatment with the pro...

0 shares

Endocrine Abstracts

PD-1/PD-L1 inhibitors and immune-related thyroid toxicity according to pre-existing thyroid dysfunction and TPO antibody levels: a single centre experience

Immune-related thyroid dysfunctions during PD-1/PD-L1 inhibitors and their association to the oncological outcome: new evidence

BiosciAbstracts